Place of flow cytometry for diagnosis and follow-up of acute leukemia;Place de la cytométrie en flux pour le diagnostic et le suivi des leucémies aiguës

Revue Francaise des Laboratoires

Volumn 2002, Issue 344, 2002, Pages 25-30

  Jouault, Hélène ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

Acute leukemias; Flow cytometry; Immunophenotyping; Minimal residual disease

Indexed keywords

EID: 15444369983     PISSN: 03389898     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0338-9898(02)80017-8     Document Type: Article

References (43)

1. Adriaansen H.J., te Boekhorst P.A., Hagemeijer A.M., van der Schoot C.E., Delwel H.R., Van Dongen J.J., A leukemia M4 with bone marrow eosinophilia (M4Eo) and inv(16)(p13q22) exhibits a specific immunophenotype with CD2 expression, Blood 81 (1993) 3043-3051.
2. Andrieu V., Radford-Weiss I., Troussard X., Chane C., Valensi F., Guesnu M., Haddad E., Viguier F., Dreyfus F., Varet B., Flandrin G., Macintyre E., Molecular detection of t(8 ;21)/AML1-ETO: correlation with cytogenetics, morphology and immunophenotype, Br. J. Haematol. 92 (1996) 855-865.
3. Arber D.A., Glackin C., Lowe G., Medeiros L.J., Slovak M.L., Presence of t(8;21)(q22;q22) in myeloperoxydase-positive myeloid surface antigen-negative acute myeloid leukaemia, Am. J. Clin. Pathol. 107 (1997) 68-73.
4. Bene M.C., Castoldi G., Knapp W., Ludwig W.D., Matutes E., Van't Vee M.B., Proposals for immunological classification of acute leukemias, Leuk. 9 (1995) 1783-1786.
5. Bene M.C., Bernier M., Casasnovas R.O., Castoldi G., Doekharan D., van der Holt B., Knapp W., Lemez P., Ludwig W.D., Matutes E., Orfao A., Schoch C., Sperling C., Van't Veer M.B., for the European group for the immunological characterization of leukemias, Acute myeloid leukemia MO : hematological, immunophenotypic and cytogenetic characteristics and their prognostic significance : an analysis in 241 patients, Br. J. Haematol. 113 (2001) 737-745.
6. Betz S.A., Foucar K., Head D.R., Chen I.M., Willman C.L., False-positive flow cytometric platelet glycoprotein IIb/IIIa expression in myeloid leukemias secondary to platelet adherence to blasts, Blood 79 (1992) 2399-2403.
7. Braylan R.C., Orfao A., Borowitz M., Davis B., Optimal number of reagents required to evaluate hematolymphoid neoplasias : Results of an international consensus meeting, Cytometry 46 (2001) 23-27.
8. Brunning R.D., Matutes E., Flandrin G., Vardiman J., Bennett J., Head D., Harris N.L., Acute myeloid leukemia with recurrent genetic abnormalities. In : Jaffe E.S., Harris N.L., Stein H., Vardiman J.W. (Eds): World health organization classification of tumours, Pathology and genetics of tumours of haematopoietic and lymphoid tissues, IARC Press, Lyon 2001.
9. Brunning R.D., Matutes E., Flandrin G., Vardiman J., Bennett J., Head D., Harris N.L., Acute myeloid leukaemia not otherwise categorised. In : Jaffe E.S., Harris N.L., Stein H., Vardiman J.W. (Eds) : World health organization classification of tumours, Pathology and genetics of tumours of haematopoietic and lymphoid tissues, IARC Press, Lyon 2001.
10. Brunning R.D., Matutes E., Borowitz M., Flandrin G., Head D., Vardiman J., Bennett J., Acute leukemias of ambiguous lineage. In : Jaffe E.S., Harris N.L., Stein H., Vardiman J.W. (Eds) : World health organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues, IARC Press, Lyon 2001.
11. Campana D., Pui C.H., Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance, Blood 85 (1995) 1416-1434.
12. Campana D., Coustan-Smith E., Detection of minimal residual disease in acute leukemia by flow cytometry, Cytometry 38 (1999) 139-152.
13. Chaperot L., Bendriss N., Manches O., Gressin R., Maynadie M., Trimoreau F., Orfeuvre H., Corront B., Feuillard J., Sotto J.J., Bensa J.C., Brière F., Plumas J., Jacob M.C., Identification of a leukemic counterpart of the plasmacytoid dendritic cells, Blood 97 (2001) 3210-3217.
14. Copelan E.A., Mc Guire E.A , The biology and treatment of acute lymphoblastic leukemia in adults, Blood 85 (1995) 1151-1168.
15. Cortes J.E., Kantardjian H.M., Acute lymphoblastic leukemia. A comprehensive review with emphasis on biology and therapy, Cancer 76 (1995) 2393-2417.
16. Coustan-Smith E., Sancho J., Hancock M.L., Boyett J.L., Behm F.G., Raimondi S.C., Sandlund J.T., Rivera G.K., Rubnitz J.E., Ribeiro R.C., Pui C.H., Campana D., Clinical importance of minimal residual disease in chilhood acute lymphoblastic leukaemia, Blood 96 (2000) 2691-2696.
17. Czuczman M.S., Dodge R.K., Stewart C.C., Frankel S.R., Davey F.R., Powell B.L., Szatrowski T.P., Schiffer C.A., Larson R.A., Bloomfield C.D., Value of immunophenptyping in intensively treated adult acute lymphoblastic leukemia: Cancer and leukemia group B study 8364, Blood 93 (1999) 3931-3939.
18. Diebold J., Jaffe E.S., Raphael M., Warnke R.A., Burkitt lymphoma. In : Jaffe E.S., Harris N.L., Stein H., Vardiman J.W. (Eds) : World health organization classification of tumours. Patholoy and genetics of tumours of haematopoietic and lymphoid tissues, IARC Press, Lyon 2001.
19. Farahat N., Lens D., Zomas A., Morilla R., Matutes E., Catovski D., Quantitative flow cytometry can distinguish between normal and leukaemic B-cell precursors, Br. J. Haematol. 91 (1995) 640-646.
20. Farahat N., Morilla A., Owusu-Ankomah K., Morilla R., Pinkerton C.R., Treleaven J.G., Matutes E., Powles R.L., Catovski D., Detection of minimal residual disease in B-lineage acute lymphoblastic leukaemia by quantitative flow cytometry, Br. J. Haematol. 101 (1998) 158-164.
21. Ferrara F., Di Noto R., Annunziata M., Copia C., Lo Pardo C., Boccuni P., Sebastio L., Del Vecchio L., Immunophenotypic analysis enables the correct prediction of t(8;21) in acute myeloid leukaemia, Br. J. Haematol. 102 (1998) 444-448.
22. Feuillard J., Jacob M.C., Valensi F., Maynadié M., Gressin R., Chaperot L., Brignole-Beaudoin F., Drenou B., Duchayne E., Falkenrodt A., Garand R., Homolle E., Husson B., Kuhlein E., Le Calvez G., Sainty D., Sotto M.F., Trimoreau F., Béné M.C., Clinical and biologic features of CD4+CD56+ malignancies, Blood 99 (2002) 1556-1563.
23. Garand R., Imbert M., Jouault H., Preudhomme C., Lepelley P., Garnache F., Salaun V., Malet M., Maynadie M., Casanovas O., Trimoreau F., Arnoulet C., Sainty D., Latger-Cannard V., Buisine J., Pedron B., Fenneteau O., Daliphard S., Sudaka I., Philip P., Graupe français d'hématologie cellulaire, Blood 11 (2001) Abstract no 3334.
24. Griesinger F., Pirò-Noack M., Kaib N., Falk M., Renziehausen A., Troff C., Grove D., Schnittger S., Büchner T., Ritter J., Hiddemann W., Wörmann B., Leukaemia-associated immunophenotypes (LAIP) are observed in 90 % of adult and childhood acute lymphoblastic leukaemia : detection in remission marrow preditcs outcome, Br. J. Haematol. 105 (1999) 241-255.
25. Hurwitz CA, Raimondi S.C., Head D., Krance R., Mirro J., Kalwinsky D.K., Ayers G.D., Behm F.G., Distinctive immunophenotypic features of t(8;21)(q22;q22) acute myeloblastic leukemia in children, Blood 80 (1992) 3182-3188.
26. Jennings C.D., Foon K.A., Recent advances in flow cytometry: Application to the diagnosis of hematologic malignancies, Blood 90 (1997) 2863-2892.
27. Kersey J.H., Fifty years of studies of the biology and therapy of chilhood leukaemia, Blood 90 (1997) 4243-4251.
28. Lacombe F., Durrieu F., Briais A., Dumain P., Belloc F., Bascans E., Reiffers J., Boisseau M.R., Bernard Ph., Flow cytometry CD45 gating for immunophenotyping of acute myeloid leukaemia, Leuk. 11 (1997) 1878-1886.
29. Liu Yin J.A., Tobal K., Detection of minimal residual disease in acute myeloid leukemia: Methodologies, clinical and biological significance, Br. J. Haematol. 106 (1991) 578-590.
30. Ludwig W.D., Rieder H., Bartam C.R., Heinze B., Schwartz S., Gassman W., Löffler H., Hossfeld D., Heil G., Handt S., Heyll A., Diedrich H., Fischer K., Weiss A., Völkers B., Aydemir U., Fonatsch C., Gökbuget N., Thiel E., Hoelzer D., Immunophenotypic and genotypic features, clinical characteristics, and treatment outcome of adult pro-B acute lymphoblastic leukaemia, Results of the german multicenter trials GMALL 03/87 and 04/87, Blood 92 (1998) 1898-1909.
31. McCoy J.P., Davis B.H., Report of the clinical practice task force survey of the clinical cytometry society, Cytom. 46 (2001) 177-183.
32. McKenna R.W., Washington L.T., Aquino D.B., Picker L.J., Kroft S.H., Immunophenotypic analysis of hematogones (B-lymphocyte precursors) in 662 consecutive bone marrow specimens by 4-color flow cytometry, Blood 98 (2001) 2498-2507.
33. Orfao A., Schmitz G., Brando B., Ruiz-Arguelles A., Basso G., Braylan R., Rothe G., Lacombe F., Lanza S., Papa S., Lucio P., San Miguel J.F. and the Standardization committee on clinical flow cytometry of the international federation, Clinically useful information provided by the flow cytometric immunophenotyping of hematological malignancies : current status and future directions, Clini. Chem. 45 (1999) 1708-1717.
34. Paredes-Aguilera R., Romero-Guzman L., Lopez-Santiago N., Burbano-Ceron L., Camacho-Del Monte O., Nieto-Martinez S., Flow cytometric analysis of cell-surface and intracellular antigens in the diagnosis of acute leukaemia, Am. J. Hematol. 68 (2001) 69-74.
35. Pui C.H., Evans W.E., Acute lymphoblastic leukaemia, N. Engl. J. Med. 339 (1998) 605-615.
36. Rainer R.O., Hodges L., Seltzer G.T., CD45 gating correlates with bone marrow differential, Cytom. 22 (1995) 139-145.
37. Reading C.L., Estey E.H., Huh Y.O., Claxton D.F., Sanchez G., Terstappen L.W.M.M., O'Brien M.C., Baron S., Deisseroth A.B., Expression of unusual immunophenotype combinations in acute myelogenous leukaemia, Blood 81 (1993) 3083-3090.
38. San Miguel J.F., Martìnez A., Macedo A., Vidriales M.B., López-Berges C., González M., Caballero D., Garcìa-Marcos M.A., Ramos F., Fernández-Calvo J., Calmuntia M.J., Diaz-Mediavilla J., Orfao A., Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients, Blood, 90 (1997) 2465-2470.
39. San Miguel J.F., Vidriales M., Lòpez-Berges C., Dìaz-Mediavilla J., Gutiérrez N., Can̄izo C., Ramos F., Calmuntia M.J., Pérez J.J., González M., Orfao A., Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment dtratification, Blood 98 (2001) 1746-1751.
40. Seshi B., Kashyap A., Bennett J.M., Acute leukemia with an unusual phenotype : myeloperoxydase (+), CD13 (-), CD14 (-) and CD33 (-), Br. J. Haematol. 81 (1992) 374-377.
41. Uckun F.M., Sensel M.G., Sun L., Steinherz P.G., Trigg M.E., Heerema N.A., Sather H.N., Reaman G.H., Gaynon P.S., Biology and treatment of chilhood T-lineage acute lymphoblastic leukaemia, Blood 91 (1998) 735-746.
42. Venditti A., Del Poeta G., Buccisano F., Tamburini A., Cox M.C., Stasi R., Bruno A., Aronica G., Maffei L., Suppo G., Simone M.D., Forte L., Cordero V., Postorino M., Tiffili V., Isacchi G., Masi M., Papa G., Amadori S., Minimally differentiated acute myeloid leukemia (AML-M0) : comparison of 25 cases with other french-american-british subtypes, Blood 89 (1997) 621-629.
43. Voisine C., Trinité B., Josien R., Les cellules dendritiques, Rev. Fr. Lab. 341 (2002) 31-41.